TN2011000246A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number: TN2011000246A1
Authority: TN; Tunisia
Prior art keywords: organic compounds; compounds; pyrazolo; pyrimidin; thio
Prior art date: 2008-12-06

Application number

TN2011000246A

Other languages

English (en)

Inventor

Lawrence P Wennogle

Peng Li

Zeng Hailin

Zhao Jun

Original Assignee

Intra Cellular Therapies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-06

Filing date

2011-05-17

Publication date

2012-12-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42233533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000246(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-17 Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc

2012-12-17 Publication of TN2011000246A1 publication Critical patent/TN2011000246A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TN2011000246A 2008-12-06 2011-05-17 Organic compounds TN2011000246A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12044208P	2008-12-06	2008-12-06
PCT/US2009/006439 WO2010065149A1 (fr)	2008-12-06	2009-12-07	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2011000246A1 true TN2011000246A1 (en)	2012-12-17

Family

ID=42233533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000246A TN2011000246A1 (en)	2008-12-06	2011-05-17	Organic compounds

Country Status (23)

Country	Link
US (4)	US8536159B2 (fr)
EP (1)	EP2367429B1 (fr)
JP (1)	JP5778582B2 (fr)
KR (1)	KR20110095881A (fr)
CN (1)	CN102231953A (fr)
AU (1)	AU2009322901A1 (fr)
BR (1)	BRPI0922348A2 (fr)
CA (1)	CA2740391A1 (fr)
CL (1)	CL2011001263A1 (fr)
CO (1)	CO6390083A2 (fr)
CR (1)	CR20110312A (fr)
DO (1)	DOP2011000173A (fr)
EA (1)	EA201170770A1 (fr)
EC (1)	ECSP11011184A (fr)
ES (1)	ES2638912T3 (fr)
IL (1)	IL213314A0 (fr)
MA (1)	MA32938B1 (fr)
MX (1)	MX2011005933A (fr)
PE (1)	PE20110922A1 (fr)
SG (1)	SG171775A1 (fr)
TN (1)	TN2011000246A1 (fr)
WO (1)	WO2010065149A1 (fr)
ZA (1)	ZA201103631B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101248050B (zh)	2005-06-06	2013-07-17	武田药品工业株式会社	有机化合物
MX2008015489A (es)	2006-06-06	2009-01-13	Intra Cellular Therapies Inc	Compuestos organicos.
WO2008063505A1 (fr) *	2006-11-13	2008-05-29	Intra-Cellular Therapies, Inc.	Composés organiques
US9006258B2 (en)	2006-12-05	2015-04-14	Intra-Cellular Therapies, Inc.	Method of treating female sexual dysfunction with a PDE1 inhibitor
CN101969774A (zh) *	2007-12-06	2011-02-09	细胞内治疗公司	有机化合物
KR20120012831A (ko)	2007-12-06	2012-02-10	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
MX2011005933A (es) *	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
EA201170768A1 (ru)	2008-12-06	2012-05-30	Интра-Селлулар Терапиз, Инк.	Органические соединения
US8633180B2 (en)	2008-12-06	2014-01-21	Intra-Cellular Therapies, Inc.	Organic compounds
US8859564B2 (en)	2008-12-06	2014-10-14	Intra-Cellular Therapies, Inc.	Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1
WO2010065153A1 (fr)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Composés organiques
JP5784501B2 (ja) *	2008-12-06	2015-09-24	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
EP2400970A4 (fr) *	2009-02-25	2012-07-18	Intra Cellular Therapies Inc	Inhibiteur de pde 1 pour troubles ophtalmiques
WO2010132127A1 (fr)	2009-05-13	2010-11-18	Intra-Cellular Therapies, Inc.	Composés organiques
JP2013507360A (ja)	2009-10-08	2013-03-04	イントラ−セルラー・セラピーズ・インコーポレイテッド	ホスホジエステラーゼ１−標的トレーサーおよび方法
EP2575817A4 (fr)	2010-05-31	2014-01-08	Intra Cellular Therapies Inc	Composés organiques
EP2590657A4 (fr)	2010-05-31	2014-02-12	Intra Cellular Therapies Inc	Composés organiques
EP2576551A4 (fr)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	Composés organiques
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
WO2012171016A1 (fr) *	2011-06-10	2012-12-13	Intra-Cellular Therapies, Inc.	Composés organiques
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
LT2782584T (lt)	2011-11-23	2021-09-10	Therapeuticsmd, Inc.	Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
MX357320B (es)	2012-06-18	2018-07-04	Dart Neuroscience Cayman Ltd	Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida.
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
AR091507A1 (es)	2012-06-21	2015-02-11	Intra Cellular Therapies Inc	SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9801882B2 (en)	2013-02-17	2017-10-31	Intra-Cellular Therapies, Inc.	Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2968338B1 (fr)	2013-03-15	2019-01-09	Intra-Cellular Therapies, Inc.	Inhibiteurs de pde1 utilisés dans le traitement et/ou la prévention de blessures du snc et de maladies, de troubles ou de blessures du snp
PL2970279T3 (pl)	2013-03-15	2021-05-31	Intra-Cellular Therapies, Inc.	Związki organiczne
RU2675851C2 (ru) *	2013-06-21	2018-12-25	Интра-Селлулар Терапиз, Инк.	Кристаллические формы свободного основания
JP6696904B2 (ja)	2014-01-08	2020-05-20	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	製剤および医薬組成物
US10206932B2 (en)	2014-05-22	2019-02-19	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
WO2015196186A1 (fr)	2014-06-20	2015-12-23	Intra-Cellular Therapies, Inc.	Composés organiques
CA2951284A1 (fr)	2014-07-29	2016-02-04	Therapeuticsmd, Inc.	Creme transdermique
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
EP3177627B1 (fr)	2014-08-07	2019-07-24	Intra-Cellular Therapies, Inc.	Derives de imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one avec activite inhibitrice de la pde1
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
JP6596080B2 (ja)	2014-09-17	2019-10-23	イントラ−セルラー・セラピーズ・インコーポレイテッド	化合物および方法
HK1243935A1 (zh)	2014-12-06	2018-07-27	Intra-Cellular Therapies, Inc.	有机化合物
WO2016090380A1 (fr)	2014-12-06	2016-06-09	Intra-Cellular Therapies, Inc.	Composés organiques
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017172795A1 (fr)	2016-03-28	2017-10-05	Intra-Cellular Therapies, Inc.	Nouvelles compositions et méthodes
WO2017173044A1 (fr)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
JP2019513709A (ja)	2016-04-01	2019-05-30	セラピューティックスエムディーインコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ，Ｉｎｃ．	ステロイドホルモン薬学的組成物
US11291666B2 (en)	2016-09-12	2022-04-05	Intra-Cellular Therapies, Inc.	Uses
EP3746081A4 (fr)	2018-01-31	2021-10-27	Intra-Cellular Therapies, Inc.	Nouvelles utilisations
US20210205310A1 (en)	2018-05-25	2021-07-08	Intra-Cellular Therapies, Inc.	Organic compounds
WO2020069043A1 (fr)	2018-09-25	2020-04-02	Intra-Cellular Therapies, Inc.	Nouvelles utilisations
US11628171B2 (en)	2019-03-13	2023-04-18	Children's Medical Center Corporation	Method for treating brain or nerve injury
US20220184240A1 (en)	2019-04-12	2022-06-16	Intra-Cellular Therapies, Inc.	Organic compounds
US12410175B2 (en)	2019-09-03	2025-09-09	Intra-Cellular Therapies, Inc.	Compounds
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
US12435093B2 (en)	2020-05-06	2025-10-07	Intra-Cellular Therapies, Inc.	Free base crystals
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666908A (en)	1985-04-05	1987-05-19	Warner-Lambert Company	5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
IL98559A0 (en) *	1990-06-21	1992-07-15	Schering Corp	Polycyclic guanine derivatives
US5202328A (en)	1991-03-06	1993-04-13	Merck & Co., Inc.	Substituted fused pyrimidinones
US5294612A (en)	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
EP0686157A1 (fr)	1993-02-26	1995-12-13	Schering Corporation	Derives de guanine 2-benzyle-polycyclique et procede de preparation
GB9315017D0 (en)	1993-07-20	1993-09-01	Glaxo Lab Sa	Chemical compounds
US5824683A (en)	1995-11-28	1998-10-20	Schering Corporation	2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
IT1291372B1 (it)	1997-05-21	1999-01-07	Schering Plough S P A	Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6013621A (en)	1997-10-17	2000-01-11	The Rockfeller University	Method of treating psychosis and/or hyperactivity
GB9722520D0 (en)	1997-10-24	1997-12-24	Pfizer Ltd	Compounds
US6133273A (en)	1998-05-08	2000-10-17	American Home Products Corporation	Pyrazolopyrimidine-2,4-dione sulfonamides
DE19931206A1 (de)	1999-07-07	2001-01-11	Stief Christian	Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
CN1377354A (zh)	1999-09-30	2002-10-30	纽罗杰有限公司	某些亚烷基二胺一取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
HK1049834A1 (zh)	1999-10-11	2003-05-30	辉瑞大药厂	用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
IL152925A (en)	1999-10-21	2010-04-15	Pfizer	Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
WO2001078711A2 (fr)	2000-04-19	2001-10-25	Lilly Icos, Llc.	Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson
CA2436911A1 (fr)	2001-03-16	2002-09-26	Pfizer Inc.	Composes pyrazolo[4,3-d]pyrimidinone en tant qu'inhibiteurs de gmpc pde
WO2002088079A2 (fr)	2001-05-01	2002-11-07	Bristol-Myers Squibb Company	Inhibiteurs doubles de pde 7 et pde 4
SE0102315D0 (sv)	2001-06-28	2001-06-28	Astrazeneca Ab	Compounds
DE60226615D1 (fr)	2001-08-28	2008-06-26	Schering Corp
CA2459161A1 (fr)	2001-08-31	2003-03-13	The Rockefeller University	Activite de phosphodiesterase et regulation de la signalisation a mediation par phosphodiesterase 1-b dans le cerveau
US6943171B2 (en)	2001-11-09	2005-09-13	Schering Corporation	Polycyclic guanine derivative phosphodiesterase V inhibitors
EP1476200A4 (fr)	2002-02-21	2008-08-13	Univ Rockefeller	Compositions et methodes de regulation de la signalisation dependant du calcium dans le cerveau
GB0230045D0 (en)	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
EP1613747A1 (fr)	2003-03-31	2006-01-11	Pfizer Products Inc.	Structure cristalline de 3',5'-phosphodiesterase nucleotidique cyclique 1d(pde1b) et ses utilisations
AU2004226353A1 (en)	2003-04-01	2004-10-14	Laboratoires Serono Sa	Inhibitors of phosphodiesterases in infertility
AU2004270713A1 (en)	2003-09-05	2005-03-17	Aventis Pharmaceuticals Inc.	Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
CN101248050B (zh)	2005-06-06	2013-07-17	武田药品工业株式会社	有机化合物
WO2007025103A2 (fr)	2005-08-23	2007-03-01	Intra-Cellular Therapies, Inc.	Composes organiques
MX2008015489A (es)	2006-06-06	2009-01-13	Intra Cellular Therapies Inc	Compuestos organicos.
US20070286890A1 (en) *	2006-06-07	2007-12-13	John Garnett Walt	Eyelash applicator and method
WO2008063505A1 (fr) *	2006-11-13	2008-05-29	Intra-Cellular Therapies, Inc.	Composés organiques
US9006258B2 (en)	2006-12-05	2015-04-14	Intra-Cellular Therapies, Inc.	Method of treating female sexual dysfunction with a PDE1 inhibitor
KR20120012831A (ko)	2007-12-06	2012-02-10	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
CN101969774A (zh)	2007-12-06	2011-02-09	细胞内治疗公司	有机化合物
WO2010065153A1 (fr)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Composés organiques
US8633180B2 (en)	2008-12-06	2014-01-21	Intra-Cellular Therapies, Inc.	Organic compounds
EA201170768A1 (ru)	2008-12-06	2012-05-30	Интра-Селлулар Терапиз, Инк.	Органические соединения
US8859564B2 (en)	2008-12-06	2014-10-14	Intra-Cellular Therapies, Inc.	Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1
MX2011005933A (es) *	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
JP5784501B2 (ja)	2008-12-06	2015-09-24	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
EP2400970A4 (fr)	2009-02-25	2012-07-18	Intra Cellular Therapies Inc	Inhibiteur de pde 1 pour troubles ophtalmiques
WO2010132127A1 (fr)	2009-05-13	2010-11-18	Intra-Cellular Therapies, Inc.	Composés organiques
JP2013507360A (ja)	2009-10-08	2013-03-04	イントラ−セルラー・セラピーズ・インコーポレイテッド	ホスホジエステラーゼ１−標的トレーサーおよび方法
EP2590657A4 (fr)	2010-05-31	2014-02-12	Intra Cellular Therapies Inc	Composés organiques
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
EP2576551A4 (fr)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	Composés organiques
EP2575817A4 (fr)	2010-05-31	2014-01-08	Intra Cellular Therapies Inc	Composés organiques
WO2012171016A1 (fr) *	2011-06-10	2012-12-13	Intra-Cellular Therapies, Inc.	Composés organiques

2009
- 2009-12-07 MX MX2011005933A patent/MX2011005933A/es not_active Application Discontinuation
- 2009-12-07 CA CA2740391A patent/CA2740391A1/fr not_active Abandoned
- 2009-12-07 CN CN2009801480893A patent/CN102231953A/zh active Pending
- 2009-12-07 KR KR1020117013115A patent/KR20110095881A/ko not_active Withdrawn
- 2009-12-07 ES ES09830744.0T patent/ES2638912T3/es active Active
- 2009-12-07 US US13/133,033 patent/US8536159B2/en active Active
- 2009-12-07 MA MA33969A patent/MA32938B1/fr unknown
- 2009-12-07 EP EP09830744.0A patent/EP2367429B1/fr active Active
- 2009-12-07 BR BRPI0922348-7A patent/BRPI0922348A2/pt not_active IP Right Cessation
- 2009-12-07 PE PE2011001169A patent/PE20110922A1/es not_active Application Discontinuation
- 2009-12-07 JP JP2011539520A patent/JP5778582B2/ja not_active Expired - Fee Related
- 2009-12-07 WO PCT/US2009/006439 patent/WO2010065149A1/fr not_active Ceased
- 2009-12-07 EA EA201170770A patent/EA201170770A1/ru unknown
- 2009-12-07 AU AU2009322901A patent/AU2009322901A1/en not_active Abandoned
- 2009-12-07 SG SG2011036589A patent/SG171775A1/en unknown
2011
- 2011-05-17 ZA ZA2011/03631A patent/ZA201103631B/en unknown
- 2011-05-17 TN TN2011000246A patent/TN2011000246A1/fr unknown
- 2011-05-30 CL CL2011001263A patent/CL2011001263A1/es unknown
- 2011-06-02 IL IL213314A patent/IL213314A0/en unknown
- 2011-06-06 DO DO2011000173A patent/DOP2011000173A/es unknown
- 2011-06-06 CR CR20110312A patent/CR20110312A/es unknown
- 2011-06-29 CO CO11081343A patent/CO6390083A2/es active IP Right Grant
- 2011-07-05 EC EC2011011184A patent/ECSP11011184A/es unknown
2013
- 2013-09-06 US US14/020,016 patent/US20140005155A1/en not_active Abandoned
2014
- 2014-10-03 US US14/506,394 patent/US20150038474A1/en not_active Abandoned
2015
- 2015-04-30 US US14/700,746 patent/US20160083390A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA201170770A1 (ru)	2012-02-28
JP2012510993A (ja)	2012-05-17
US20160083390A1 (en)	2016-03-24
MX2011005933A (es)	2011-12-16
ES2638912T3 (es)	2017-10-24
EP2367429B1 (fr)	2017-06-07
CN102231953A (zh)	2011-11-02
US20150038474A1 (en)	2015-02-05
SG171775A1 (en)	2011-07-28
ECSP11011184A (es)	2011-10-31
US20140005155A1 (en)	2014-01-02
DOP2011000173A (es)	2011-10-31
US20110245214A1 (en)	2011-10-06
CO6390083A2 (es)	2012-02-29
BRPI0922348A2 (pt)	2015-08-11
CL2011001263A1 (es)	2011-11-18
WO2010065149A1 (fr)	2010-06-10
EP2367429A4 (fr)	2012-06-06
PE20110922A1 (es)	2012-01-22
KR20110095881A (ko)	2011-08-25
AU2009322901A1 (en)	2010-06-10
MA32938B1 (fr)	2012-01-02
IL213314A0 (en)	2011-07-31
EP2367429A1 (fr)	2011-09-28
CR20110312A (es)	2011-10-28
ZA201103631B (en)	2013-05-29
CA2740391A1 (fr)	2010-06-10
JP5778582B2 (ja)	2015-09-16
US8536159B2 (en)	2013-09-17

Publication	Publication Date	Title
TN2011000246A1 (en)	2012-12-17	Organic compounds
EP2698160A3 (fr)	2014-07-23	Composés organiques
TN2011000247A1 (en)	2012-12-17	Organic compounds
WO2013192556A3 (fr)	2014-02-27	Cristaux de sel
NZ623922A (en)	2015-09-25	Novel tricyclic compounds
WO2006133261A3 (fr)	2007-06-21	Composes organiques
TN2011000245A1 (en)	2012-12-17	Organic compounds
TN2011000244A1 (en)	2012-12-17	Organic compounds
EP2608669A4 (fr)	2014-01-22	Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
EP2387315A4 (fr)	2012-05-30	Imidazo[1,2-a]pyridines et imidazo[1,2-b]pyridazines utilisés en tant qu'inhibiteurs de la kinase mark
PH12016501164A1 (en)	2016-08-15	Heteroaryl substituted nicotinamide compounds
IL216427A (en)	2017-11-30	Solid Pharmaceutical Components of 4 - {[9-Chloro-7- (2-Fluoro-6-Methoxyphenyl) - h5- Pyrimido [d-5,4] [2] Benzazepine-2-ram] Amino} -2-Acid Oxidizer Benzoic, its salts and processes for making them
IL206811A0 (en)	2010-12-30	NOVEL PYRAZOLO [3,4-d] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS
GEP20146098B (en)	2014-05-27	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
CO6390079A2 (es)	2012-02-29	Compuestos organicos
WO2010012781A3 (fr)	2010-05-14	Nouvelles formes cristallines de sels d’un dérivé de 5,6,7,8-tétrahydro-1,2,4- triazolo[4,3-a]pyrazine
NZ594508A (en)	2013-12-20	[1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
WO2012060590A3 (fr)	2012-06-28	Hydrate de tartrate de 1-{(2s)-2-amino-4-[2,4-bis(trifluorométhyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoropipéridin-2-one
IL213589A0 (en)	2011-07-31	DIPYRIDO [2,3-d;4-d] PYRROL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2010011546A3 (fr)	2010-08-12	Composés acycliques ayant une affinité pour le récepteur 5-ht6
EP2048139A4 (fr)	2010-09-01	PROCÉDÉ POUR LA PRODUCTION DE (±)-3a,6,6,9a-TÉTRAMÉTHYLDÉCAHYDRONAPHTO[2,1-b]FURAN-2(1H)-ONE
WO2007031977A3 (fr)	2007-06-07	Inhibiteurs de la phosphodiesterase
UA98797C2 (en)	2012-06-25	2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro -1h-pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors
CY1114796T1 (el)	2016-12-14	Οργανικες ενωσεις
HK1178745A (en)	2013-09-19	Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate